Harmony Biosciences Beats on Patient Growth but Misses Badly on Profit — Can a One-Drug Company Afford Rising Costs and a Leadership Transition at the Same Time?

Shares of Harmony Biosciences cratered 9.5% to $33.52 on November 4 after the narcolepsy-drug maker reported third-quarter results that missed Wall Street expectations on both the top and bottom lines. The miss raises a pointed question: is the company's only marketed product growing fast enough to absorb a new, heavier cost structure?

Earnings Fell Even as Sales Grew — and the Gap Was Wide

Harmony reported EPS of $0.81, $0.30 below the analyst consensus of $1.11.

Revenue came in at $268.9 million, up 12% year over year but below the estimated $273.08 million. The revenue shortfall was modest — about 1.5% — but the earnings miss was severe, roughly 27% below consensus. Pretax profit of $59.25 million landed well under the $85.44 million estimate , underscoring that cost pressures, not a demand collapse, drove the disappointment.

New Royalty and Milestone Bills Are Eating Into Margins

Cost of revenue jumped to $80.7 million, or 30% of net revenue, compared with 25% a year ago, primarily due to new royalty costs.

The company pointed to higher milestone and royalty charges tied to its Novitium license agreement — essentially, fees Harmony pays to a partner for drug-supply rights. For shareholders, this means each new dollar of revenue now converts into fewer cents of profit, a trend management must explain more fully.

Patient Demand Looks Healthy, but It's the Only Bright Spot

Harmony added 400 net patients in the quarter, bringing the average count to roughly 9,350.

Full-year revenue guidance of $1.0 billion to $1.04 billion was reaffirmed. That means the company still expects a strong Q4 finish — but investors are now less willing to take that at face value given the quarter's margin erosion.

A CEO Exit Adds Another Variable

The board appointed COO Peter Anastasiou as CEO effective January 1, 2027, replacing retiring nine-year veteran Jeffrey Dayno. The transition was anticipated, but it coincides with the company's most challenging earnings print in recent memory — and with Phase 1b results for its next-generation sleep drug BP-205 expected in Q1 2027 . The incoming CEO will inherit a single-product company that still needs to prove it can grow earnings, not just sales.